Allchem Lifescience IPO is a proposed Mainboard Book Built public issue by Allchem Lifescience Limited. The proposed public issue comprises a fresh issue of equity shares aggregating up to ₹190 crore along with an Offer for Sale of up to 71.55 lakh equity shares by promoter selling shareholders. The company has proposed to list its equity shares on both the BSE and NSE.
The fresh issue proceeds are proposed to be used primarily for repayment or pre-payment of certain borrowings, with the remaining amount intended for general corporate purposes and business requirements. The Offer for Sale consists of shares offered by Kantilal Ramanlal Patel and Manisha Bipin Patel, while the proceeds from the OFS will be received by the respective selling shareholders.
Allchem Lifescience Limited is a Gujarat-based manufacturer of key starting materials, generic API intermediates and specialty chemicals. The company has developed capabilities across multiple organic chemistries and manufactures products used in pharmaceutical, agrochemical, veterinary, plastics, electrochemical and other industrial applications.
The company operates a manufacturing facility at Manjusar, Vadodara, Gujarat. It has developed the capability to manufacture 263 products and serves domestic as well as international customers. As of December 2024, the company served customers across 13 states in India and 22 countries overseas.
Table of Contents
Allchem Lifescience IPO Details
| Information | Details |
|---|---|
| IPO Name | Allchem Lifescience IPO |
| Company Name | Allchem Lifescience Limited |
| IPO Type | Book Built Issue |
| IPO Category | Mainboard IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | |
| Issue Size | Up to ₹905 Crore* |
| Fresh Issue | Up to ₹190 Crore |
| Offer for Sale | Up to 71.55 Lakh Equity Shares |
| IPO Open Date | |
| IPO Close Date | |
| Anchor Investor Bidding | |
| Basis of Allotment | |
| Refund Initiation | |
| Shares Credited to Demat Account | |
| Listing Date | |
| Listing Exchange | BSE & NSE |
| Lot Size | |
| Registrar | MUFG Intime India Private Limited |
| Book Running Lead Manager | Emkay Global Financial Services Limited |
*The proposed overall offer size depends on the final Offer Price for the OFS portion. The DRHP specifies a fresh issue of up to ₹190 crore and an OFS of up to 71.55 lakh shares. The price band and minimum bid lot are to be decided and announced before the IPO opens.
Objects of the Allchem Lifescience IPO
The company proposes to utilise the net proceeds from the fresh issue primarily towards repayment or pre-payment, in full or in part, of certain outstanding borrowings.
An estimated ₹130 crore is proposed to be utilised towards repayment or pre-payment of certain borrowings. The balance of the net proceeds is proposed to be used for general corporate purposes and business requirements.
The proceeds from the Offer for Sale will be received by the respective selling shareholders and will not form part of the company’s funds.
Allchem Lifescience IPO Dates
| IPO Event | Date |
|---|---|
| Anchor Investor Bidding | |
| IPO Opening Date | |
| IPO Closing Date | |
| Basis of Allotment | |
| Refund Initiation | |
| Shares Credited to Demat Account | |
| Listing Date |
The company has not announced the final IPO bidding schedule, allotment date or listing date in the currently available public information. These details are expected to be updated after the relevant offer documents and price-band announcement are made available.
Allchem Lifescience IPO Reservation
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% |
| Non-Institutional Investors (NII) | Not Less Than 15% |
| Retail Individual Investors (RII) | Not Less Than 35% |
The reservation structure disclosed in the DRHP provides for not more than 50% of the Offer for QIBs, not less than 15% for NIIs and not less than 35% for Retail Individual Investors. The final allocation will depend on the applicable offer structure and the number of valid applications received during the IPO.
Allchem Lifescience IPO Lot Size
| Application | Shares | Amount |
|---|---|---|
| Retail Minimum | ||
| Retail Maximum | ||
| S-HNI Minimum | ||
| S-HNI Maximum | ||
| B-HNI Minimum |
The minimum bid lot and corresponding application amounts have not yet been announced. These details will be updated after the company announces the price band and minimum bid lot.
About Allchem Lifescience Limited
Allchem Lifescience Limited is a pharmaceutical and specialty chemical manufacturing company based in Vadodara, Gujarat. The company was incorporated in 2017 and subsequently changed its name from Allchem Lifescience Private Limited to Allchem Lifescience Limited.
The company focuses on the manufacturing of key starting materials, generic API intermediates and specialty chemicals. Its products are used as inputs in pharmaceutical manufacturing and other industrial applications.
Allchem Lifescience has developed capabilities across a broad range of organic chemical compounds and has the ability to manufacture 263 products. Its product development approach focuses on identifying products with potential demand, particularly products that are difficult to source domestically or have import-substitution potential, followed by development and commercial-scale manufacturing.
The company operates its manufacturing facility at Manjusar near Vadodara, Gujarat. As of December 2024, the manufacturing facility had an installed equipment capacity of approximately 1,133.50 KL. The company serves customers in India and overseas markets.
Business Operations
Allchem Lifescience Limited operates in the API intermediates and specialty chemicals manufacturing segment.
- API Intermediates –The company manufactures generic API intermediates and key starting materials that are used in the production of pharmaceutical ingredients. API intermediates form a significant portion of the company’s business.
- Specialty Chemicals – The company manufactures specialty chemicals designed for specific applications and chemistries. These products serve pharmaceutical and other industrial applications.
- Piperazine Derivatives – Allchem Lifescience has developed capabilities in manufacturing piperazine derivatives, which are important intermediates used in the manufacture of certain pharmaceutical APIs, including intermediates associated with products such as quetiapine.
- Custom and Product Development – The company focuses on developing products based on customer requirements and market demand. Its product development capabilities allow it to work across different organic chemistries and develop products with potential import-substitution opportunities.
- Domestic and Export Markets – The company caters to customers across India as well as international markets. As of December 2024, it served customers across 13 Indian states and 22 countries overseas.
Industry Overview
The API intermediates and specialty chemicals industry is supported by the continued demand for pharmaceutical products, increasing outsourcing of intermediate manufacturing and the expansion of pharmaceutical manufacturing capabilities in India.
The API intermediates market is also supported by the increasing requirement for specialised chemical inputs and the growing role of contract and outsourced manufacturing. India remains an important manufacturing location for pharmaceutical and chemical companies because of its established manufacturing ecosystem and technical capabilities.
Allchem Lifescience operates in a segment where product development, manufacturing quality, customer relationships, regulatory compliance and the ability to supply specialised products are important competitive factors.
Business Strategy
Allchem Lifescience focuses on developing and manufacturing products across multiple organic chemistries and applications. The company’s strategy includes identifying products with potential market demand, developing products that may have limited domestic availability and scaling production once commercial demand is established.
The company also focuses on strengthening its manufacturing capabilities, improving product development and expanding its customer base across domestic and international markets.
Its manufacturing infrastructure, product diversification and experience in specialised chemistries are intended to support future business growth. The company also aims to maintain quality standards and expand its presence in pharmaceutical and specialty chemical applications.
Allchem Lifescience IPO Financial Information
A company’s financial performance provides valuable insights into revenue growth, profitability, operating efficiency and financial stability. Reviewing financial performance over multiple years helps investors understand the company’s ability to generate revenue and profits and manage its financial obligations.
Allchem Lifescience Financial Summary
| Particulars | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue from Operations | ₹105.71 Crore | ₹137.42 Crore | ₹152.40 Crore |
| Total Income | ₹109.81 Crore | ₹133.89 Crore | ₹152.78 Crore |
| EBITDA | ₹30.44 Crore | ₹52.29 Crore | ₹66.65 Crore |
| Profit Before Tax (PBT) | ₹28.83 Crore | ₹29.93 Crore | ₹33.06 Crore |
| Profit After Tax (PAT) | ₹17.99 Crore | ₹23.41 Crore | ₹24.15 Crore |
| Net Worth | ₹56.49 Crore | ₹79.89 Crore | ₹104.00 Crore |
| Total Borrowings | ₹97.17 Crore | ₹104.97 Crore |
FY2023 and FY2024 figures are based on the restated financial information disclosed in the DRHP, while FY2025 financial figures reported in public financial databases show revenue from operations of approximately ₹152.40 crore and PAT of approximately ₹24.15 crore.
Allchem Lifescience IPO Key Performance Indicators (KPIs)
Key Performance Indicators help investors assess profitability, operating efficiency, capital utilisation and financial strength. The DRHP disclosed the following key indicators based on the company’s restated financial information.
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 34.33% |
| Return on Capital Employed (ROCE) | 22.87% |
| Return on Net Worth (RONW) | 34.33% |
| EBITDA Margin | 38.05% |
| PAT Margin | 17.03% |
| Debt-to-Equity Ratio | 1.31 |
| Earnings Per Share (EPS) | ₹3.06 |
| Net Asset Value (NAV) Per Share | ₹10.44 |
| Price to Earnings (P/E) |
These KPI figures relate to FY2024 and are based on the company’s DRHP disclosures. The P/E ratio cannot be calculated until the final IPO price is announced.
Objects of the Allchem Lifescience IPO
The company intends to utilise the net proceeds from the fresh issue for the following purposes:
- Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings.
- General corporate purposes.
- Supporting the company’s business requirements.
The company disclosed that approximately ₹130 crore of the fresh issue proceeds is proposed to be used for repayment or pre-payment of certain borrowings. As of February 28, 2025, the company had outstanding fund-based borrowings of approximately ₹131.74 crore, excluding vehicle loans.
The proceeds from the Offer for Sale will be received by the respective promoter selling shareholders.
Allchem Lifescience IPO Listing Performance
The listing performance will reflect how the company’s equity shares perform after they are listed on the stock exchanges.
| Particular | Value |
|---|---|
| Listing Exchange | BSE & NSE |
| Listing Date | |
| Issue Price | |
| Listing Price | To be updated |
| Listing Gain | To be updated |
| Listing Gain (%) | To be updated |
The company has proposed listing its equity shares on BSE and NSE. The final issue price and listing date are not available at this stage.
Allchem Lifescience IPO Subscription Status
The subscription figures indicate the level of investor participation received during the IPO bidding period.
Allchem Lifescience IPO Subscription
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIB) | To be updated |
| Non-Institutional Investors (NII) | To be updated |
| Retail Individual Investors (RII) | To be updated |
| Employee Category | To be updated |
| Total Subscription | To be updated |
The subscription figures will be available after the IPO opens for bidding. The current public information does not provide final subscription figures because the bidding period has not yet been announced.
Allchem Lifescience IPO Review
Allchem Lifescience Limited operates in the API intermediates and specialty chemicals manufacturing industry, with capabilities spanning key starting materials, generic API intermediates and specialty chemicals. The company has developed 263 products and serves customers across domestic and international markets. Its manufacturing facility is located at Manjusar near Vadodara, Gujarat.
The company has reported growth in revenue and profitability over the financial periods disclosed in its offer documents. Revenue from operations increased from ₹108.10 crore in FY2022 to ₹137.42 crore in FY2024, while PAT increased from ₹14.14 crore to ₹23.41 crore during the same period. The company also reported a revenue CAGR of 12.75% between FY2022 and FY2024 and a PAT CAGR of 28.65% over the same period.
The IPO proceeds are primarily intended to reduce borrowings, with approximately ₹130 crore proposed for repayment or pre-payment of certain debt. Investors should also examine customer concentration, dependence on the pharmaceutical industry, raw-material availability, working-capital requirements, regulatory compliance, manufacturing risks and competition before evaluating the IPO.
Overall, the Allchem Lifescience IPO should be evaluated using the final price band, valuation, financial performance, debt position, business growth, customer concentration, industry conditions and the final offer documents once the issue details are announced.
Allchem Lifescience IPO Strengths
- Established manufacturer of API intermediates, key starting materials and specialty chemicals.
- Capability to manufacture a diversified portfolio of 263 products.
- Presence across domestic and international markets.
- Manufacturing facility located at Manjusar, Vadodara, Gujarat.
- Experience in developing products across multiple organic chemistries.
- Established relationships with pharmaceutical and chemical customers.
- Revenue and profitability growth reported across the financial periods disclosed in the DRHP.
- Proposed use of a substantial portion of fresh issue proceeds towards debt repayment.
Allchem Lifescience IPO Risk Factors
- The company is significantly dependent on demand from the pharmaceutical industry.
- Revenue is concentrated among certain key customers, creating customer concentration risk.
- The company depends on certain suppliers and the availability of required raw materials.
- API intermediates constitute a significant portion of revenue, creating product and segment concentration risk.
- Failure to meet required quality standards could affect customer relationships and business performance.
- The company depends on third-party logistics and support service providers.
- The business has working-capital requirements that may affect cash flows.
- Delayed customer payments may create credit and cash-flow risks.
- The company has outstanding borrowings and is exposed to risks associated with indebtedness.
- The business operates in a competitive pharmaceutical and specialty chemicals industry.
Allchem Lifescience IPO Promoters
Allchem Lifescience Limited has four promoters: Bipin Patel, Kantilal Ramanlal Patel, Manisha Bipin Patel and Aditi Patel. The promoter selling shareholders in the proposed OFS are Kantilal Ramanlal Patel and Manisha Bipin Patel.
Allchem Lifescience IPO Promoters Details
| Promoter | Designation |
|---|---|
| Bipin Kantilal Patel | Promoter & Managing Director |
| Kantilal Ramanlal Patel | Promoter & Whole-time Director (Technical) |
| Manisha Bipin Patel | Promoter |
| Aditi Patel | Promoter & Whole-time Director |
Allchem Lifescience IPO Management Team
The company is led by a management and Board team with experience in pharmaceutical manufacturing, chemical engineering, product development, finance and corporate governance.
Management Team
| Name | Designation |
|---|---|
| Bipin Kantilal Patel | Managing Director |
| Kantilal Ramanlal Patel | Director – Technical |
| Jigardan Gadhvi | Company Secretary & Compliance Officer |
Bipin Kantilal Patel is one of the founders and promoters of the company and oversees product development, process development and manufacturing operations. Kantilal Ramanlal Patel serves as Director – Technical and has extensive engineering and plant-management experience.
Allchem Lifescience IPO Registrar Details
The registrar is responsible for processing IPO applications, finalising the basis of allotment, crediting shares to successful applicants, initiating refunds and handling investor-related services.
| Particular | Details |
|---|---|
| Registrar Name | MUFG Intime India Private Limited |
| Website | www.in.mpms.mufg.com |
| IPO Allotment Status | To be updated |
| Email ID | [email protected] |
| Contact Number | +91 810 811 4949 |
The company’s official investor information identifies MUFG Intime India Private Limited as the Registrar and Share Transfer Agent.
Allchem Lifescience IPO Lead Manager Details
The Book Running Lead Manager is responsible for managing the IPO process, coordinating regulatory requirements and assisting the company throughout the public issue.
| Particular | Details |
|---|---|
| Lead Manager | Emkay Global Financial Services Limited |
Emkay Global Financial Services Limited has been identified as the sole Book Running Lead Manager for the proposed issue.
Allchem Lifescience Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | Allchem Lifescience Limited |
| Registered Office | Block No. 1088/B/P, 1088-A, Lamdapura Road, Village Manjusar, Tal-Savli, Vadodara, Gujarat – 391775 |
| Website | www.allchemlifescience.com |
| Email ID | [email protected] |
| Contact Number | +91 957 472 2211 |
The company’s official website lists its registered and corporate office at Manjusar, Vadodara, Gujarat, along with investor contact details.
How to Check Allchem Lifescience IPO Allotment Status
Investors can check the IPO allotment status after the basis of allotment is finalised through the registrar’s website or the relevant stock exchange IPO portal.
Through MUFG Intime India Private Limited
- Visit the official MUFG Intime IPO allotment portal.
- Select Allchem Lifescience IPO from the IPO list.
- Choose PAN Number, Application Number, or DP/Client ID.
- Enter the required details.
- Click Submit to view the allotment status.
Through BSE
- Visit the official BSE IPO allotment page.
- Select Allchem Lifescience IPO from the list of IPOs.
- Enter your PAN Number or Application Number.
- Complete the verification process if required.
- Click Search to view the allotment result.
Allchem Lifescience IPO Conclusion
Allchem Lifescience IPO provides an opportunity to participate in the proposed public issue of a Gujarat-based manufacturer of API intermediates, key starting materials and specialty chemicals. The company has developed capabilities across multiple chemistries and has a product portfolio covering 263 products.
The company has reported growth in revenue and profitability in the financial periods disclosed in its offer documents and serves customers across India and international markets. The proposed use of approximately ₹130 crore from the fresh issue towards repayment or pre-payment of borrowings is also an important aspect of the IPO structure.
However, investors should carefully consider the company’s dependence on the pharmaceutical industry, customer concentration, supplier dependence, working-capital requirements, regulatory requirements, manufacturing risks, competition and outstanding borrowings before making an investment decision.
The final assessment of the IPO will depend significantly on the price band, valuation, lot size, final issue structure, financial results and other details disclosed in the final offer documents.
Allchem Lifescience IPO FAQs
What is Allchem Lifescience IPO?
Allchem Lifescience IPO is the proposed Mainboard public issue of Allchem Lifescience Limited, a manufacturer of API intermediates, key starting materials and specialty chemicals.
What is the price band of Allchem Lifescience IPO?
The price band has not yet been announced.
What is the issue size of Allchem Lifescience IPO?
The proposed IPO comprises a fresh issue of up to ₹190 crore and an Offer for Sale of up to 71.55 lakh equity shares. The final overall issue size will depend on the final Offer Price for the OFS portion.
When will the Allchem Lifescience IPO open?
The IPO opening date has not yet been announced.
When will the Allchem Lifescience IPO close?
The IPO closing date has not yet been announced.
On which stock exchanges will Allchem Lifescience shares be listed?
The company has proposed listing its equity shares on BSE and NSE.
Who is the registrar for the Allchem Lifescience IPO?
MUFG Intime India Private Limited is the Registrar and Share Transfer Agent for the company.
What is the face value of Allchem Lifescience IPO shares?
The face value of each equity share is ₹10.
What does Allchem Lifescience Limited do?
Allchem Lifescience Limited manufactures key starting materials, generic API intermediates and specialty chemicals. The company has developed capabilities to manufacture 263 products across different organic chemistries.
What are the objects of the Allchem Lifescience IPO?
The company proposes to use approximately ₹130 crore from the fresh issue towards repayment or pre-payment of certain borrowings, while the remaining proceeds are proposed for general corporate purposes and business requirements.
